EGFR and non-small cell lung carcinoma: In contrast, anlotinib combined with ICIs exhibited a longer median PFS (4.3 months vs 3.6 months, p = 0.005), and OS (14.2 months vs 9.0 months p = 0.029) than chemotherapy for the late‐line treatment of patients with NSCLC and EGFR‐TKI resistance.36